ID: h-f9c6fa3f
Hypothesis

Microbiome-Derived Tryptophan Metabolite Neuroprotection

Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which activate aryl hydrocarbon receptors in microglia, shifting them from pro-inflammatory to anti-inflammatory phenotypes.
🧬 AHR, IL10, TGFB1🩺 neurodegeneration🎯 Composite 43%💱 $0.45▼24.4%archived
EvidencePending (0%)📖 18 cit🗣 1 debates 5 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.20 (15%) Evidence 0.30 (15%) Novelty 0.70 (12%) Feasibility 0.40 (12%) Impact 0.50 (12%) Druggability 0.30 (10%) Safety 0.60 (8%) Competition 0.50 (6%) Data Avail. 0.30 (5%) Reproducible 0.20 (5%) KG Connect 0.31 (8%) 0.427 composite
🏆 ChallengeGut Microbial Metabolites as Early Causal Drivers of Alzheimer's Pathogenesis$1.8M →

🧪 Overview

Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which activate aryl hydrocarbon receptors in microglia, shifting them from pro-inflammatory to anti-inflammatory phenotypes. Precision probiotic therapy could restore this protective pathway.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Tryptophan Dietary Intake"] -->|"substrate"| B["Gut Microbiome Metabolism"]
    B -->|"produces"| C["Indole-3-Propionic Acid"]
    C -->|"crosses BBB via MCT1/MCT2"| D["CNS Entry"]
    D -->|"ligand binding"| E["AHR Activation"]
    E -->|"transcriptional regulation"| F["IL10 Gene Expression"]
    E -->|"transcriptional regulation"| G["TGFB1 Gene Expression"]
    F -->|"anti-inflammatory"| H["Microglial M2 Polarization"]
    G -->|"immunosuppressive"| H
    H -->|"reduces"| I["Neuroinflammation"]
    I -->|"prevents"| J["Synaptic Loss"]
    I -->|"prevents"| K["Neuronal Death"]
    L["Dysbiosis"] -->|"reduces"| B
    M["Probiotic Therapy"] -->|"restores"| B
    N["AHR Agonists"] -->|"activates"| E
    O["Neuroprotection"]

    J -->|"maintains"| O
    K -->|"maintains"| O

    classDef mechanism fill:#4fc3f7,color:#0d0d1a
    classDef pathology fill:#ef5350,color:#0d0d1a
    classDef therapy fill:#81c784,color:#0d0d1a
    classDef outcome fill:#ffd54f,color:#0d0d1a
    classDef genetics fill:#ce93d8,color:#0d0d1a

    class A,C,D,E mechanism
    class L,I,J,K pathology
    class M,N therapy
    class O outcome
    class B,F,G,H genetics

⚖️ Evidence

⚖️ Evidence Matrix5 supports2 contradicts
Supports
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma.
Immunity2024PMID:38703775medium
Supports
Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
Nat Med2024PMID:38961225medium
Supports
Microbiota-indole 3-propionic acid-brain axis mediates abnormal synaptic pruning of hippocampal microglia and susceptibility to ASD in IUGR offspring.
Microbiome2023PMID:37932832medium
Supports
Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway.
CNS Neurosci Ther2023PMID:37032648medium
Supports
Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Sci Transl Med2024PMID:39167665medium
Contradicts
Indole metabolite neuroprotection has been shown in amyloidopathy contexts, but this does not prove generalizable protection across neurodegenerative diseases or precision probiotic efficacy.
Brain Behav Immun2024PMID:39197546medium
Contradicts
A comprehensive Parkinson review frames indole metabolites as an emerging and complex area rather than settled clinical neuroprotection.
Brain Res Bull2026PMID:41679674medium
📖 Linked Papers (15)Export BibTeX ↗
Figure 1
Figure 1
Progenitor-derived neurons cultured for 7 days in vitro (DIV) exhibited immature responses to GABA A receptor activation. ( a – c ) Representative pictures o...
Figure 2
Figure 2
KCC2 expression is low in progenitor-derived neurons by 7 DIV. ( a ) Little KCC2 immunofluorescence was observed in progenitor-derived neurons and P5 RGCs compa...
Figures
Figures
Figures available at source paper (no open-access XML found).
Figures
Figures
Figures available at source paper (no open-access XML found).
Gene editing.
Nature biotechnology (2020) · PubMed:32641840 ↗
No figures
[Effect of alexithymia on health anxiety: Mediating role of cognition and meta-cognition].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (2018) · PubMed:30333296 ↗
No figures
📙 Related Wiki Pages (15)

🏥 Translation

🧬 3D Protein Structure — AHR

No curated PDB or AlphaFold mapping for AHR yet. Search RCSB →

💉 Clinical Trials (5)Relevance: 44%

0
Active
0
Completed
282
Total Enrolled
PHASE1
Highest Phase
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for AHR, IL10, TGFB1 →

No DepMap CRISPR Chronos data found for AHR, IL10, TGFB1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline
2.2 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.4%
Volatility
High
0.0754
Events (7d)
2
Price History
▼24.4%

💾 Resource Usage

LLM Tokens
34,972
$0.2158
Total Cost
$0.2158

🔮 Predictions

🔎 Predictions vs Observations3 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
If hypothesis is true, intervention identify patients most likely to benefit from interventionidentify patients most likely to benefit from intervention— no observation —pending0.30
If hypothesis is true, intervention enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic paenroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokineti— no observation —pending0.30
If hypothesis is true, intervention incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signalsincorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals— no observation —pending0.30
🔮 Falsifiable Predictions (3)
pendingconf 30%
If hypothesis is true, intervention identify patients most likely to benefit from intervention
Predicted outcome: identify patients most likely to benefit from intervention
Falsification: Intervention fails to identify patients most likely to benefit from intervention
pendingconf 30%
If hypothesis is true, intervention incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals
Predicted outcome: incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or externa
Falsification: Intervention fails to incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals
pendingconf 30%
If hypothesis is true, intervention enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic parameters
Predicted outcome: enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and phar
Falsification: Intervention fails to enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic parameters
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.